Cargando…

The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()

INTRODUCTION: It is difficult to evaluate the effect of drugs clinically used for idiopathic sudden sensorineural hearing loss, mainly because its underlying mechanism remains unknown. OBJECTIVE: This study assessed the efficacy of hyperbaric oxygen therapy or ozone therapy in the treatment of idiop...

Descripción completa

Detalles Bibliográficos
Autores principales: Ergun Taşdöven, Gülin, Derin, Alper Tunga, Yaprak, Neslihan, Özçağlar, Hasan Ümit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442686/
https://www.ncbi.nlm.nih.gov/pubmed/27460341
http://dx.doi.org/10.1016/j.bjorl.2016.06.002
_version_ 1784782873158483968
author Ergun Taşdöven, Gülin
Derin, Alper Tunga
Yaprak, Neslihan
Özçağlar, Hasan Ümit
author_facet Ergun Taşdöven, Gülin
Derin, Alper Tunga
Yaprak, Neslihan
Özçağlar, Hasan Ümit
author_sort Ergun Taşdöven, Gülin
collection PubMed
description INTRODUCTION: It is difficult to evaluate the effect of drugs clinically used for idiopathic sudden sensorineural hearing loss, mainly because its underlying mechanism remains unknown. OBJECTIVE: This study assessed the efficacy of hyperbaric oxygen therapy or ozone therapy in the treatment of idiopathic sudden sensorineural hearing loss, when either therapy was included with steroid treatment. METHODS: A retrospective analysis examined 106 patients with idiopathic sudden sensorineural hearing loss seen between January 2010 and June 2012. Those with an identified etiology were excluded. The patients were divided into three treatment groups: oral steroid only (n = 65), oral steroid + hyperbaric oxygen (n = 26), and oral steroid + ozone (n = 17). Treatment success was assessed using Siegel criteria and mean gains using pre- and post-treatment audiograms. RESULTS: The highest response rate to treatment was observed in the oral steroid + ozone therapy group (82.4%), followed by the oral steroid + hyperbaric oxygen (61.5%), and oral steroid groups (50.8%). There were no significant differences in the response to treatment between the oral steroid and oral steroid + hyperbaric oxygen groups (p < 0.355). The oral steroid + ozone group showed a significantly higher response rate to treatment than the oral steroid group (p = 0.019). There were no significant differences between the oral steroid + hyperbaric oxygen and oral steroid + ozone groups (p = 0.146). CONCLUSION: The efficiency of steroid treatment in patients with severe hearing loss was low. It was statistically ascertained that adding hyperbaric oxygen or ozone therapy to the treatment contributed significantly to treatment success.
format Online
Article
Text
id pubmed-9442686
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94426862022-09-09 The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss() Ergun Taşdöven, Gülin Derin, Alper Tunga Yaprak, Neslihan Özçağlar, Hasan Ümit Braz J Otorhinolaryngol Original Article INTRODUCTION: It is difficult to evaluate the effect of drugs clinically used for idiopathic sudden sensorineural hearing loss, mainly because its underlying mechanism remains unknown. OBJECTIVE: This study assessed the efficacy of hyperbaric oxygen therapy or ozone therapy in the treatment of idiopathic sudden sensorineural hearing loss, when either therapy was included with steroid treatment. METHODS: A retrospective analysis examined 106 patients with idiopathic sudden sensorineural hearing loss seen between January 2010 and June 2012. Those with an identified etiology were excluded. The patients were divided into three treatment groups: oral steroid only (n = 65), oral steroid + hyperbaric oxygen (n = 26), and oral steroid + ozone (n = 17). Treatment success was assessed using Siegel criteria and mean gains using pre- and post-treatment audiograms. RESULTS: The highest response rate to treatment was observed in the oral steroid + ozone therapy group (82.4%), followed by the oral steroid + hyperbaric oxygen (61.5%), and oral steroid groups (50.8%). There were no significant differences in the response to treatment between the oral steroid and oral steroid + hyperbaric oxygen groups (p < 0.355). The oral steroid + ozone group showed a significantly higher response rate to treatment than the oral steroid group (p = 0.019). There were no significant differences between the oral steroid + hyperbaric oxygen and oral steroid + ozone groups (p = 0.146). CONCLUSION: The efficiency of steroid treatment in patients with severe hearing loss was low. It was statistically ascertained that adding hyperbaric oxygen or ozone therapy to the treatment contributed significantly to treatment success. Elsevier 2016-07-06 /pmc/articles/PMC9442686/ /pubmed/27460341 http://dx.doi.org/10.1016/j.bjorl.2016.06.002 Text en © 2016 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Ergun Taşdöven, Gülin
Derin, Alper Tunga
Yaprak, Neslihan
Özçağlar, Hasan Ümit
The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title_full The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title_fullStr The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title_full_unstemmed The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title_short The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
title_sort place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442686/
https://www.ncbi.nlm.nih.gov/pubmed/27460341
http://dx.doi.org/10.1016/j.bjorl.2016.06.002
work_keys_str_mv AT erguntasdovengulin theplaceofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT derinalpertunga theplaceofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT yaprakneslihan theplaceofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT ozcaglarhasanumit theplaceofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT erguntasdovengulin placeofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT derinalpertunga placeofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT yaprakneslihan placeofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss
AT ozcaglarhasanumit placeofhyperbaricoxygentherapyandozonetherapyinsuddenhearingloss